A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Zaawansowany nowotwór, który nie może być operacyjnie usunięty lub rozprzestrzeniły się przerzuty
- •Brak dostępnego leczenia, które mogłoby całkowicie wyleczyć chorobę
- •Guzy widoczne w badaniach obrazowych, które można mierzyć
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (skala ECOG 0-1)
- •Prawidłowa funkcja organów wewnętrznych (wątroba, nerki, serce)
- •Nowotwór ma określone zmiany genetyczne w ścieżce AKT/PI3K/PTEN
- •Dla raka piersi: zmutowany receptor hormonalny dodatni, HER2 ujemny i wcześniejsze leczenie inhibitorem aromatazy
- •Dla raka endometrium lub jajnika: wcześniejsze standardowe leczenie lub do 3 poprzednich linii terapii
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (18)
City of Hope
Duarte, United States
City of Hope, Irvine
Irvine, United States
Florida Cancer Specialists - Lake Nona
Orlando, United States
City of Hope, Chicago
Zion, United States
Massachusetts General Hospital
Boston, United States
Mayo Rochester
Rochester, United States
Washington Univ. School of Medicine
St Louis, United States
Nebraska Cancer Specialists
Omaha, United States
Carolina BioOncology Institute
Huntersville, United States
UH Cleveland Medical Center
Cleveland, United States
Sarah Cannon Nashville
Nashville, United States
NEXT Oncology
Austin, United States
MD Anderson Cancer Center
Houston, United States
START Center for Cancer Research
San Antonio, United States
START Center for Cancer Research
West Valley City, United States
NEXT Oncology
Fairfax, United States
Froedtert & MCW Cancer Center
Milwaukee, United States
PanOncology Trials
San Juan, Puerto Rico
Trial contact
Terremoto Biosciences, Inc. Clinical Trials Central Contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.